{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:50:40Z","timestamp":1788346240246,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020193","name":"Novartis Pharmaceuticals Australia Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020193","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.hlc.2025.07.012","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:31:58Z","timestamp":1764973918000},"page":"82-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9136-8772","authenticated-orcid":false,"given":"Ralph G.","family":"Audehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-1524","authenticated-orcid":false,"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hespe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meherin","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Santani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5291-0610","authenticated-orcid":false,"given":"Andrew M.","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2025.07.012_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart Study): case-Control Study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2025.07.012_bib2","first-page":"115","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"70","author":"Catapano","year":"2016","journal-title":"Rev Espanola Cardiol (Engl Ed)"},{"key":"10.1016\/j.hlc.2025.07.012_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2025.07.012_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b36","article-title":"Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow-up of population based Perth Monica cohort, 1984\u20132005","volume":"338","author":"Briffa","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2025.07.012_bib5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12913-017-2395-9","article-title":"The effectiveness of emergency nurse practitioner service in the management of patients presenting to rural hospitals with chest pain: a multisite prospective longitudinal nested cohort study","volume":"17","author":"Roche","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.hlc.2025.07.012_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.07.012_bib7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.18773\/austprescr.2024.019","article-title":"Lipid-lowering therapy in patients with a \u2018normal\u2019 LDL-C","volume":"47","author":"Hackket","year":"2024","journal-title":"Aust Prescr"},{"key":"10.1016\/j.hlc.2025.07.012_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.hlc.2025.02.102","article-title":"National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: comprehensive Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025","volume":"34","author":"Brieger","year":"2025","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2025.07.012_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ahj.2023.12.010","article-title":"Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention","volume":"269","author":"Mazhar","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2025.07.012_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025813","article-title":"Intensity of and adherence to lipid-lowering therapy as predictors of major adverse cardiovascular outcomes in patients with coronary heart disease","volume":"11","author":"Mazhar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hlc.2025.07.012_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10557-021-07199-7","article-title":"Switching, persistence and adherence to statin therapy: a retrospective cohort study using the Australian national pharmacy data","volume":"36","author":"Talic","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hlc.2025.07.012_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bmjqs-2022-015699","article-title":"Comparing secondary prevention for patients with coronary heart disease and stroke attending Australian general practices: a cross-sectional study using nationwide electronic database","volume":"33","author":"Yue","year":"2024","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.hlc.2025.07.012_bib13","series-title":"Heart, Stroke and Vascular Disease: Australian Facts","year":"2024"},{"key":"10.1016\/j.hlc.2025.07.012_bib14","series-title":"National Vascular Disease Prevention Alliance. Guidelines for the Management of Absolute Cardiovascular Disease Risk","author":"Lalor","year":"2012"},{"key":"10.1016\/j.hlc.2025.07.012_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5694\/mja16.00368","article-title":"National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016","volume":"205","author":"Chew","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.hlc.2025.07.012_bib16","volume":"10","author":"Booth","year":"2017"},{"key":"10.1016\/j.hlc.2025.07.012_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hlc.2025.07.012_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archinte.167.8.847","article-title":"Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use","volume":"167","author":"Brookhart","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hlc.2025.07.012_bib19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s00392-023-02257-6","article-title":"Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany","volume":"113","author":"Koenig","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hlc.2025.07.012_bib20","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease commission: reducing the global burden by 2030","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2025.07.012_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017310","article-title":"Recurrent atherosclerotic cardiovascular event rates differ among patients meeting the very high risk definition according to age, sex, race\/ethnicity, and socioeconomic status","volume":"9","author":"An","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hlc.2025.07.012_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11096-022-01470-z","article-title":"Association between health literacy and medication adherence in chronic diseases: a recent systematic review","volume":"45","author":"Hyvert","year":"2023","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.hlc.2025.07.012_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MOL.0000000000000896","article-title":"Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease","volume":"34","author":"Karalis","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.hlc.2025.07.012_bib24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1080\/00325481.2022.2117498","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","volume":"134","author":"Underberg","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.hlc.2025.07.012_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186458","article-title":"Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence","volume":"12","author":"N\u00e1fr\u00e1di","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.hlc.2025.07.012_bib26","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1080\/03007995.2021.1973396","article-title":"Lipid management across Europe in the real-world setting: a rapid evidence review","volume":"37","author":"Barrios","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hlc.2025.07.012_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"BioMed Res Int"},{"issue":"11","key":"10.1016\/j.hlc.2025.07.012_bib28","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the Da Vinci Study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.hlc.2025.07.012_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","article-title":"Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322 153 patients","volume":"16","author":"Navar","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hlc.2025.07.012_bib30","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-Intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2025.07.012_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307237","article-title":"Prevalence of cardiovascular drug-related adverse drug reactions consultations in UK primary care: a cross-sectional study","volume":"19","author":"Insani","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.hlc.2025.07.012_bib32","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2025.07.012_bib33","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.012_bib34","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.012_bib35","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.07.012_bib36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamacardio.2019.2306","article-title":"Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial","volume":"4","author":"Bach","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hlc.2025.07.012_bib37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ahj.2018.09.003","article-title":"Countering clinical inertia in lipid management: expert workshop summary","volume":"206","author":"Zullig","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2025.07.012_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1755-5922.12236","article-title":"Ezetimibe: use, costs, and adverse events in Australia","volume":"35","author":"Hollingworth","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.hlc.2025.07.012_bib39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000536392","article-title":"Optimizing post-acute coronary syndrome dyslipidemia management: insights from the North American acute coronary syndrome reflective III","volume":"149","author":"Alanezi","year":"2024","journal-title":"Cardiology"},{"key":"10.1016\/j.hlc.2025.07.012_bib40","volume":"14","author":"Sarak","year":"2021"},{"key":"10.1016\/j.hlc.2025.07.012_bib41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/heartjnl-2013-305296","article-title":"Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand","volume":"100","author":"Redfern","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.hlc.2025.07.012_bib42","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/imj.15700","article-title":"Barriers to prescribing proprotein convertase subtilisin-kexin Type 9 Inhibitors after coronary revascularisation","volume":"53","author":"Nguy","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.hlc.2025.07.012_bib43","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1093\/eurheartj\/ehae558","article-title":"Variation in secondary prevention of coronary heart disease: the Interaspire Study","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.07.012_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.japh.2020.09.002","article-title":"Patient-reported barriers to statin adherence: excerpts from a motivational interviewing intervention in older adults","volume":"61","author":"Vadhariya","year":"2021","journal-title":"J Am Pharm Assoc (2003)"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625015604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625015604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:34:54Z","timestamp":1768401294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950625015604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1443950625015604"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2025.07.012","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}